Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.49 |
| ▸ | CCR1 | P32246 | 8/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | FPR3 | P25089 | 1/20 | 0.44 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178283 | 1.00 | PTGDR2 (0.49) | PTGDR2CCR1MGLLFPR3GPR65 | |
| SCHEMBL4178390 | 0.87 | PTGDR2 (0.52) | PTGDR2CCR1FPR3GPR65GPR35 | |
| SCHEMBL21816571 | 0.85 | MEN1 (0.55) | CCR1MGLLALDH1A1SMN1; SMN2 | |
| SCHEMBL21816573 | 0.85 | MEN1 (0.55) | CCR1MGLLALDH1A1SMN1; SMN2 | |
| SCHEMBL1704761 | 0.85 | CCR1 (0.44) | PTGDR2CCR1MGLLFPR3GPR65 | |
| SCHEMBL1703905 | 0.84 | PDK1 (0.51) | PTGDR2MGLLSIGMAR1 | |
| SCHEMBL28653669 | 0.83 | MGLL (0.51) | PTGDR2CCR1MGLLFPR3GPR65 | |
| SCHEMBL28653667 | 0.83 | MGLL (0.51) | PTGDR2CCR1MGLLFPR3GPR65 | |
| SCHEMBL28927825 | 0.83 | MGLL (0.51) | PTGDR2CCR1MGLLFPR3GPR65 | |
| SCHEMBL14645770 | 0.83 | MGLL (0.56) | PTGDR2CCR1MGLLALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317041-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-11-28 | — | — | US | disclosed |
| US-8536182-B2 | Benzylpiperazine derivatives and their medical use | GLAXO GROUP LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| EP-1907374-B1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GPR68, GPR88, GPR55 | PTGDR2 37/4885CCR1 1073/4885MGLL 1542/4885 |
| US-20130317041-A1 | COMPOUNDS | GPR68, GPR88, GPR35 | PTGDR2 115/4885CCR1 900/4885MGLL 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.